Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the channel in its native membrane environment in open, closed and inactivated forms and the ensemble virtual screening accounting for conformational mobility in each of these states. Tentative binding pockets are considered inside the pore, in the gating region and in the allosteric locations to cover the whole spectrum of possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q14721

UPID:
KCNB1_HUMAN

ALTERNATIVE NAMES:
Delayed rectifier potassium channel 1; Voltage-gated potassium channel subunit Kv2.1

ALTERNATIVE UPACC:
Q14721; Q14193

BACKGROUND:
The protein Kv2.1, or Potassium voltage-gated channel subfamily B member 1, is integral to the regulation of potassium transport across cell membranes, affecting neurons, muscle cells, and endocrine cells. It ensures proper action potential repolarization and modulates electrical excitability in the brain, playing a role in various physiological processes, including neuron excitability, insulin secretion, and cardiac function.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in Developmental and Epileptic Encephalopathy 26, where patients exhibit multiple seizure types and cognitive delays, Kv2.1 represents a promising target for drug discovery. Exploring Kv2.1's mechanisms offers a pathway to novel therapeutic approaches for managing epilepsy and enhancing neurodevelopmental outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.